Monte Carlo analysis of a new model-based method for insulin sensitivity testing.

Insulin resistance (IR), or low insulin sensitivity, is a major risk factor in the pathogenesis of type 2 diabetes and cardiovascular disease. A simple, high resolution assessment of IR would enable earlier diagnosis and more accurate monitoring of intervention effects. Current assessments are either too intensive for clinical settings (Euglycaemic Clamp, IVGTT) or have too low resolution (HOMA, fasting glucose/insulin). Based on high correlation of a model-based measure of insulin sensitivity and the clamp, a novel, clinically useful test protocol is designed with: physiological dosing, short duration (<1 h), simple protocol, low cost and high repeatability. Accuracy and repeatability are assessed with Monte Carlo analysis on a virtual clamp cohort (N=146). Insulin sensitivity as measured by this test has a coefficient of variation (CV) of CV(SI)=4.5% (90% CI: 3.8-5.7%), slightly higher than clamp ISI (CV(ISI)=3.3% (90% CI: 3.0-4.0%)) and significantly lower than HOMA (CV(HOMA)=10.0% (90% CI: 9.1-10.8%)). Correlation to glucose and unit normalised ISI is r=0.98 (90% CI: 0.97-0.98). The proposed protocol is simple, cost effective, repeatable and highly correlated to the gold-standard clamp.

Model-based insulin and nutrition administration for tight glycaemic control in critical care.

OBJECTIVE: Present a new model-based tight glycaemic control approach using variable insulin and nutrition administration. BACKGROUND: Hyperglycaemia is prevalent in critical care. Current published protocols use insulin alone to reduce blood glucose levels, require significant added clinical effort, and provide highly variable results. None directly address both the practical clinical difficulties and significant patient variation seen in general critical care, while also providing tight control. METHODS: The approach presented manages both nutritional inputs and exogenous insulin infusions using tables simplified from a model-based, computerised protocol. Unique delivery aspects include bolus insulin delivery for safety and variable enteral nutrition rates. Unique development aspects include the use of simulated virtual patient trials created from retrospective data. The model, protocol development, and first 50 clinical case results are presented. RESULTS: High qualitative correlation to within +/-10% between simulated virtual trials and published clinical results validates the overall approach. Pilot tests covering 7358 patient hours produced an average glucose of 5.9 +/- 1.1 mmol/L. Time in the 4-6.1 mmol/L band was 59%, with 84% in 4.0-7.0 mmol/L, and 92% in 4.0-7.75 mmol/L. The average feed rate was 63% of patient specific goal feed and the average insulin dose was 2.6U/hour. There was one hypoglycaemic measurement of 2.1 mmol/L. No departures from protocol or clinical interventions were required at any time. SUMMARY: Modulating both low dose insulin boluses and nutrition input rates challenges the current practice of using only insulin in larger doses to reduce hyperglycaemic levels. Clinical results show very tight control in safe glycaemic bands. The approach could be readily adopted in any typical ICU.

Development of a model-based clinical sepsis biomarker for critically ill patients.

Sepsis occurs frequently in the intensive care unit (ICU) and is a leading cause of admission, mortality, and cost. Treatment guidelines recommend early intervention, however positive blood culture results may take up to 48 h. Insulin sensitivity (S(I)) is known to decrease with worsening condition and could thus be used to aid diagnosis. Some glycemic control protocols are able to accurately identify insulin sensitivity in real-time. Hourly model-based insulin sensitivity S(I) values were calculated from glycemic control data of 36 patients with sepsis. The hourly S(I) is compared to the hourly sepsis score (ss) for these patients (ss=0-4 for increasing severity). A multivariate clinical biomarker was also developed to maximize the discrimination between different ss groups. Receiver operator characteristic (ROC) curves for severe sepsis (ss ≥ 2) are created for both S(I) and the multivariate clinical biomarker. Insulin sensitivity as a sepsis biomarker for diagnosis of severe sepsis achieves a 50% sensitivity, 76% specificity, 4.8% positive predictive value (PPV), and 98.3% negative predictive value (NPV) at an S(I) cut-off value of 0.00013 L/mU/min. Multivariate clinical biomarker combining S(I), temperature, heart rate, respiratory rate, blood pressure, and their respective hourly rates of change achieves 73% sensitivity, 80% specificity, 8.4% PPV, and 99.2% NPV. Thus, the multivariate clinical biomarker provides an effective real-time negative predictive diagnostic for severe sepsis. Examination of both inter- and intra-patient statistical distribution of this biomarker and sepsis score shows potential avenues to improve the positive predictive value.

A benchmark data set for model-based glycemic control in critical care.

BACKGROUND: Hyperglycemia is prevalent in critical care. That tight control saves lives is becoming more clear, but the "how" and "for whom" in repeating the initial results remain elusive. Model-based methods can provide tight, patient-specific control, as well as providing significant insight into the etiology and evolution of this condition. However, it is still often difficult to compare results due to lack of a common benchmark. This article puts forward a benchmark data set for critical care glycemic control in a medical intensive care unit (ICU). Based on clinical patient data from SPecialized Relative Insulin and Nutrition Tables (SPRINT) studies, it provides a benchmark for comparing and analyzing performance in model-based glycemic control. METHODS: Data from 20 of the first 150 postpilot patients treated under SPRINT are presented. All patients had longer than a 5-day length of stay (LoS) in the Christchurch ICU. The benchmark data set matches overall patient data and glycemic control results for the entire cohort and this particular LoS >5-day group. The mortality outcome (n =3, 15%) also matches SPRINT results for this patient group. RESULTS: Data cover 20 patients and 6372 total patient hours with an average of 339.4 hours per patient. It includes insulin and nutrition inputs along with 4182 blood glucose measurements at an average of 224.3 measurements per patient, averaging a measurement approximately every 1.5 hours (16 per day). Data are available via download in a Microsoft Excel format. A series of cumulative distribution functions and tables are used to summarize data in this article. CONCLUSION: Model-based methods can provide tighter, more adaptable "one method fits all" solutions using methods that enable patient-specific modeling and control. A benchmark data set will enable easier model and protocol development for groups lacking clinical data, as well as providing a benchmark to compare results of different protocols on a single (virtual) cohort based on real clinical data.

Overview of glycemic control in critical care: relating performance and clinical results.

BACKGROUND: Hyperglycemia is prevalent in critical care and tight control can save lives. Current ad-hoc clinical protocols require significant clinical effort and produce highly variable results. Model-based methods can provide tight, patient specific control, while addressing practical clinical difficulties and dynamic patient evolution. However, tight control remains elusive as there is not enough understanding of the relationship between control performance and clinical outcome. METHODS: The general problem and performance criteria are defined. The clinical studies performed to date using both ad-hoctitration and model-based methods are reviewed. Studies reporting mortality outcome are analysed in terms of standardized mortality ratio (SMR) and a 95(th) percentile (+/-2sigma) standard error (SE(95%)) to enable better comparison across cohorts. RESULTS: Model-based control trials lower blood glucose into a 72-110 mg/dL band within 10 hours, have target accuracy over 90%, produce fewer hypoglycemic episodes, and require no additional clinical intervention. Plotting SMR versus SE(95%) shows potentially high correlation (r=0.84) between ICU mortality and tightness of control. SUMMARY: Model-based methods provide tighter, more adaptable one method fits all solutions, using methods that enable patient-specific modeling and control. Correlation between tightness of control and clinical outcome suggests that performance metrics, such as time in a relevant glycemic band, may provide better guidelines. Overall, compared to the current one size fits all sliding scale and ad-hoc regimens, patient-specific pharmacodynamic and pharmacokinetic model-based, or one method fits all control, utilizing computational and emerging sensor technologies, offers improved treatment and better potential outcomes when treating hyperglycemia in the highly dynamic critically ill patient.

Clinical validation of a model-based glycaemic control design approach and comparison to other clinical protocols.

Hyperglycaemia is prevalent in critical care and tight control can reduce mortality from 9-43% depending on the level of control and the cohort. This research presents a table-based method that varies both insulin dose and nutritional input to achieve tight control. The system mimics a previously validated model-based system, but can be used for long term, large patient number clinical evaluation. This paper evaluates this method in simulation using retrospective data and then compares clinical measurements over 15,000 patient hours to validate the models and development approach. This validation thus also validates the in silico comparison to the landmark clinical tight glycaemic control protocols. Overall, an average clinical glucose level is 5.9 +/- 1.0 mmol/L, matching simulation, however the overall clinical glucose distribution is slightly tighter than that obtained in simulation, indicating that the retrospective virtual trial design approach is slightly conservative. Finally, the model based approach is shown to have tighter control than existing, more ad-hoc clinical approaches based on the simulation results that qualitatively match reported clinical results, but also show significant variation around the average levels obtained in both the hypo-and hyperglycaemic ranges.